Terminated PHASE3 INTERVENTIONAL 2-arm NCT02072226

A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke (PRISMS)

A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)

Sponsor: Genentech, Inc.

Conditions Stroke

Interventions Alteplase Alteplase Placebo Aspirin Aspirin Placebo

Updated 12 times since 2017 Last updated: Jun 4, 2018 Started: May 31, 2014 Primary completion: Mar 22, 2017 Completion: Mar 22, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated due to slow enrollment.

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

Other Stroke trials with similar outcome

Browse all Stroke trials

This PHASE3 trial investigates Stroke and is currently terminated or withdrawn. Genentech, Inc. leads this study, which shows 12 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3

▶ Show 7 earlier versions

Aug 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jun 2018 — Aug 2018 [monthly]

Terminated PHASE3
Jun 2017 — Jun 2018 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
May 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE3

Status: Terminated → Active Not Recruiting
Mar 2017 — May 2017 [monthly]

Terminated PHASE3

Status: Recruiting → Terminated
Feb 2017 — Mar 2017 [monthly]

Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE3

First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.

Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Allentown, United States , Baltimore, United States , Birmingham, United States , Bradenton, United States , Brooklyn, United States , Buffalo, United States , Chapel Hill, United States , Charleston, United States , Chattanooga, United States and 63 more locations